FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,099 | -75.2% | 2,405 | -44.4% | 0.00% | – |
| Q2 2023 | $20,596 | +61.2% | 4,327 | +93.1% | 0.00% | – |
| Q1 2023 | $12,773 | -3.1% | 2,241 | +71.6% | 0.00% | – |
| Q4 2022 | $13,178 | -95.7% | 1,306 | -90.5% | 0.00% | -100.0% |
| Q3 2022 | $307,000 | +3311.1% | 13,730 | +3631.0% | 0.00% | – |
| Q2 2022 | $9,000 | -18.2% | 368 | +22.7% | 0.00% | – |
| Q1 2022 | $11,000 | -60.7% | 300 | -37.5% | 0.00% | – |
| Q4 2021 | $28,000 | -31.7% | 480 | -30.7% | 0.00% | – |
| Q3 2021 | $41,000 | -39.7% | 693 | -12.3% | 0.00% | – |
| Q2 2021 | $68,000 | +58.1% | 790 | +51.3% | 0.00% | – |
| Q1 2021 | $43,000 | +290.9% | 522 | +353.9% | 0.00% | – |
| Q4 2020 | $11,000 | +1000.0% | 115 | +576.5% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 17 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | -93.3% | 17 | -98.2% | 0.00% | – |
| Q3 2018 | $15,000 | +50.0% | 922 | +7.2% | 0.00% | – |
| Q2 2018 | $10,000 | – | 860 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |